PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
30545467-3	2018	Cobicistat-boosted darunavir with emtricitabine and tenofovir alafenamide co-formulation (DRV/c/FTC/TAF), with trade name Symtuza , is the first STR based on a protease inhibitor (PI).	Cobicistat	0-10	TATA-box binding protein associated factor 8	Homo sapiens	100-103
31034908-4	2019	The present study was aimed to investigate the translation of in vitro MATE1/2K inhibition to clinical creatinine increase (cobicistat) and lack of it (ritonavir) considering their intracellular concentrations in renal proximal tubules.	Cobicistat	124-134	solute carrier family 47 member 1	Homo sapiens	71-76
31034908-7	2019	Ritonavir and cobicistat are MATE1 and MATE2K inhibitors with IC50 values of 3.1 and 90 muM (ritonavir), and 4.4 and 3.2 muM (cobicistat), respectively.	Cobicistat	14-24	solute carrier family 47 member 1	Homo sapiens	29-34
31034908-7	2019	Ritonavir and cobicistat are MATE1 and MATE2K inhibitors with IC50 values of 3.1 and 90 muM (ritonavir), and 4.4 and 3.2 muM (cobicistat), respectively.	Cobicistat	14-24	solute carrier family 47 member 2	Homo sapiens	39-45
31034908-7	2019	Ritonavir and cobicistat are MATE1 and MATE2K inhibitors with IC50 values of 3.1 and 90 muM (ritonavir), and 4.4 and 3.2 muM (cobicistat), respectively.	Cobicistat	14-24	latexin	Homo sapiens	88-91
31034908-7	2019	Ritonavir and cobicistat are MATE1 and MATE2K inhibitors with IC50 values of 3.1 and 90 muM (ritonavir), and 4.4 and 3.2 muM (cobicistat), respectively.	Cobicistat	14-24	latexin	Homo sapiens	121-124
31034908-8	2019	However, the unbound cytosolic concentrations (Cu,cytosol) of ritonavir and cobicistat in human renal proximal tubule epithelial cells, 0.065 and 0.10 muM, respectively, after incubation with the clinical maximum total plasma concentrations at pharmacoenhancer doses does not support inhibition in vivo; Cu,cytosol >30 fold lower than IC50s.	Cobicistat	76-86	latexin	Homo sapiens	151-154
30508308-1	2019	Darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) is an oral once-daily single-tablet regimen for the treatment of human immunodeficiency virus-1 infection.	Cobicistat	10-20	TATA-box binding protein associated factor 8	Homo sapiens	64-67
31933482-1	2019	BACKGROUND: Cobicistat (COBI), a CYP3A inhibitor, is a pharmacokinetic enhancer that increases exposures of the HIV protease inhibitors (PIs) atazanavir (ATV) and darunavir (DRV).	Cobicistat	12-22	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	33-38
31933482-1	2019	BACKGROUND: Cobicistat (COBI), a CYP3A inhibitor, is a pharmacokinetic enhancer that increases exposures of the HIV protease inhibitors (PIs) atazanavir (ATV) and darunavir (DRV).	Cobicistat	24-28	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	33-38
31933482-11	2019	CONCLUSIONS: Consistent with COBI-mediated CYP3A inhibition, drospirenone exposure increased following coadministration with COBI-containing regimens, with a greater increase with ATV+COBI.	Cobicistat	29-33	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	43-48
30798679-1	2019	Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) is a potent fixed-dose, once-daily regimen for HIV-1 treatment and has rare emergence of drug resistance.	Cobicistat	13-23	TATA-box binding protein associated factor 8	Homo sapiens	67-70
30951643-1	2019	INTRODUCTION: Drugs used in HIV treatment; all protease inhibitors, some non-nucleoside reverse transcriptase inhibitors, and pharmacoenhancers ritonavir and cobicistat can inhibit cytochrome P450 (CYP) enzymes.	Cobicistat	158-168	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	181-196
30951643-1	2019	INTRODUCTION: Drugs used in HIV treatment; all protease inhibitors, some non-nucleoside reverse transcriptase inhibitors, and pharmacoenhancers ritonavir and cobicistat can inhibit cytochrome P450 (CYP) enzymes.	Cobicistat	158-168	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	198-201
27843352-10	2016	Therefore, isoenzyms different from CYP3A4 are supposed to be less affected by cobicistat, and thus fewer drug-drug interactions are expected.	Cobicistat	79-89	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	36-42
30252923-0	2018	Glomerular filtration rate estimated by cystatin C formulas in HIV-1 patients treated with dolutegravir, rilpivirine or cobicistat.	Cobicistat	120-130	cystatin C	Homo sapiens	40-50
28961682-0	2018	Effect of Cobicistat on Tenofovir Disoproxil Fumarate (TDF): What Is True for TAF May Also Be True for TDF.	Cobicistat	10-20	TATA-box binding protein associated factor 8	Homo sapiens	78-81
28895486-8	2017	The EVG/c/TDF/FTC contains cobicistat, a strong cytochrome P450 3A4 (CYP3A4) inhibitor, which can potentiate drug interactions involving metabolizing of medications via this pathway.	Cobicistat	27-37	sex determining region Y	Homo sapiens	10-13
28895486-8	2017	The EVG/c/TDF/FTC contains cobicistat, a strong cytochrome P450 3A4 (CYP3A4) inhibitor, which can potentiate drug interactions involving metabolizing of medications via this pathway.	Cobicistat	27-37	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	48-67
28895486-8	2017	The EVG/c/TDF/FTC contains cobicistat, a strong cytochrome P450 3A4 (CYP3A4) inhibitor, which can potentiate drug interactions involving metabolizing of medications via this pathway.	Cobicistat	27-37	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	69-75
28848011-0	2017	Differential Influence of the Antiretroviral Pharmacokinetic Enhancers Ritonavir and Cobicistat on Intestinal P-Glycoprotein Transport and the Pharmacokinetic/Pharmacodynamic Disposition of Dabigatran.	Cobicistat	85-95	ATP binding cassette subfamily B member 1	Homo sapiens	110-124
27809711-9	2016	Renal AEs were more frequent when TDF was taken with protease inhibitor (PI)- or cobicistat-containing ART.	Cobicistat	81-91	sex determining region Y	Homo sapiens	34-37
29649076-9	2018	Coadministration with P-gp/BCRP inhibitors such as cobicistat or PI-based regimens (ATV + RTV, LPV/r, or DRV + RTV) resulted in a range of 6%-183% increases in TAF and 105%-316% increases in TFV exposure, whereas coadministration with a P-gp inducer, efavirenz, resulted in a 15%-24% decrease in TAF and TFV exposure.	Cobicistat	51-61	ATP binding cassette subfamily B member 1	Homo sapiens	22-26
29649076-9	2018	Coadministration with P-gp/BCRP inhibitors such as cobicistat or PI-based regimens (ATV + RTV, LPV/r, or DRV + RTV) resulted in a range of 6%-183% increases in TAF and 105%-316% increases in TFV exposure, whereas coadministration with a P-gp inducer, efavirenz, resulted in a 15%-24% decrease in TAF and TFV exposure.	Cobicistat	51-61	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	27-31
29649076-9	2018	Coadministration with P-gp/BCRP inhibitors such as cobicistat or PI-based regimens (ATV + RTV, LPV/r, or DRV + RTV) resulted in a range of 6%-183% increases in TAF and 105%-316% increases in TFV exposure, whereas coadministration with a P-gp inducer, efavirenz, resulted in a 15%-24% decrease in TAF and TFV exposure.	Cobicistat	51-61	ATP binding cassette subfamily B member 1	Homo sapiens	237-241
28891378-0	2018	In vitro inhibition of human UGT isoforms by ritonavir and cobicistat.	Cobicistat	59-69	UDP glucuronosyltransferase family 1 member A complex locus	Homo sapiens	29-32
28891378-3	2018	The manufacturer"s data suggests that cobicistat is a more selective CYP3A4 inhibitor than ritonavir.	Cobicistat	38-48	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	69-75
28891378-4	2018	However, the inhibitory effect of ritonavir and cobicistat on human UDP glucuronosyltransferase (UGT) enzymes in Phase II metabolism is not established.	Cobicistat	48-58	UDP glucuronosyltransferase family 1 member A complex locus	Homo sapiens	68-95
28891378-4	2018	However, the inhibitory effect of ritonavir and cobicistat on human UDP glucuronosyltransferase (UGT) enzymes in Phase II metabolism is not established.	Cobicistat	48-58	UDP glucuronosyltransferase family 1 member A complex locus	Homo sapiens	97-100
29767543-3	2018	Cobicistat-boosted darunavir along with emtricitabine and tenofovir alafenamide co-formulation (DRV/c/FTC/TAF or the trade name Symtuza ) is the first marketed protease inhibitor-based fixed-dose combination regimen for the treatment of HIV infection.	Cobicistat	0-10	TATA-box binding protein associated factor 8	Homo sapiens	106-109
28960344-1	2017	OBJECTIVES: Ritonavir and cobicistat are strong inhibitors of human cytochrome P450-3A (CYP3A) isoforms, and are used clinically as pharmacokinetic boosting agents for other antiretroviral drugs.	Cobicistat	26-36	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	68-86
28960344-1	2017	OBJECTIVES: Ritonavir and cobicistat are strong inhibitors of human cytochrome P450-3A (CYP3A) isoforms, and are used clinically as pharmacokinetic boosting agents for other antiretroviral drugs.	Cobicistat	26-36	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	88-93
28960344-2	2017	Data reported by the manufacturer suggest that cobicistat is a more selective inhibitor of CYP3A than ritonavir.	Cobicistat	47-57	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	91-96
28960344-6	2017	KEY FINDINGS: Ritonavir and cobicistat both were strong inhibitors of CYP3A4, with IC50 values of 0.014 and 0.032 mum, respectively.	Cobicistat	28-38	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	70-76
28960344-10	2017	CONCLUSIONS: Consistent with previous reports, both ritonavir and cobicistat were highly potent inhibitors of CYP3A.	Cobicistat	66-76	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	110-115
28443391-3	2017	Areas covered: Atazanavir sulfate + cobicistat (ATV/c) was recently approved for the treatment of HIV-1 infection.	Cobicistat	36-46	nibrin	Homo sapiens	48-53
28443391-4	2017	Bioequivalence between cobicistat (COBI) and ritonavir (RTV) as a pharmacoenhancer of ATV was established.	Cobicistat	23-33	nibrin	Homo sapiens	86-89
28443391-4	2017	Bioequivalence between cobicistat (COBI) and ritonavir (RTV) as a pharmacoenhancer of ATV was established.	Cobicistat	35-39	nibrin	Homo sapiens	86-89
27171740-1	2016	Coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide (E/C/F/TAF) has high efficacy and improved renal and bone safety in multiple phase 3 trials; TAF single agent is being studied in 2 phase 3 trials in patients with chronic hepatitis B.	Cobicistat	27-37	TATA-box binding protein associated factor 8	Homo sapiens	173-176
27697800-1	2016	Ritonavir and cobicistat, used as pharmacokinetic enhancers in combination with some antiretrovirals (ARVs) for the treatment of HIV, are potent inhibitors of the CYP3A4 isoenzyme.	Cobicistat	14-24	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	163-169
27697800-2	2016	Most glucocorticoids are metabolised via the CYP3A4 pathway and iatrogenic Cushing"s syndrome (ICS), with possible secondary adrenal insufficiency (SAI), is a recognised complication following co-administration with ritonavir or cobicistat.	Cobicistat	229-239	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	45-51
25164142-6	2014	Both agents inhibit CYP3A4, with cobicistat being a more specific CYP inhibitor than ritonavir.	Cobicistat	33-43	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	20-26
26945713-3	2016	Cobicistat and ritonavir are equally strong inhibitors of cytochrome P450 (CYP) 3A4 and consequently were shown to be equivalent pharmacokinetic enhancers for elvitegravir and for the PIs atazanavir and darunavir.	Cobicistat	0-10	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	58-73
26945713-3	2016	Cobicistat and ritonavir are equally strong inhibitors of cytochrome P450 (CYP) 3A4 and consequently were shown to be equivalent pharmacokinetic enhancers for elvitegravir and for the PIs atazanavir and darunavir.	Cobicistat	0-10	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	75-78
26945713-4	2016	Since cobicistat is a more selective CYP inhibitor than ritonavir and is devoid of enzyme-inducing properties, differences are expected in their interaction profiles with some co-medications.	Cobicistat	6-16	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	37-40
27196356-1	2016	Cobicistat and ritonavir are structurally distinct compounds that both potently inhibit cytochrome P450 (CYP) 3A, the metabolizing enzyme primarily responsible for the elimination of several antiretroviral medications, and, as such, are pharmacokinetic boosters for antiretroviral agents that require longer dosing intervals.	Cobicistat	0-10	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	88-112
26935921-8	2016	Consistent with the previous report, CYP3A4 and CYP2D6 were determined as the major enzymes that contribute to COBI metabolism.	Cobicistat	111-115	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	37-43
26935921-8	2016	Consistent with the previous report, CYP3A4 and CYP2D6 were determined as the major enzymes that contribute to COBI metabolism.	Cobicistat	111-115	cytochrome P450 family 2 subfamily D member 6	Homo sapiens	48-54
25331712-9	2015	However, the INI elvitegravir, which is given in combination with cobicistat, requires a dose of estrogen of at least 30 microg.	Cobicistat	66-76	PHD finger protein 5A	Homo sapiens	13-16
26872388-0	2016	Effect of Ethanol on the Metabolic Characteristics of HIV-1 Integrase Inhibitor Elvitegravir and Elvitegravir/Cobicistat with CYP3A: An Analysis Using a Newly Developed LC-MS/MS Method.	Cobicistat	110-120	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	126-131
26872388-12	2016	However, in the presence of COBI we were unable to determine these parameters effectively because COBI, being a strong inhibitor of CYP3A4, blocked the EVG/ethanol-CYP3A4 interactions.	Cobicistat	98-102	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	132-138
26872388-12	2016	However, in the presence of COBI we were unable to determine these parameters effectively because COBI, being a strong inhibitor of CYP3A4, blocked the EVG/ethanol-CYP3A4 interactions.	Cobicistat	98-102	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	164-170
26872388-13	2016	Docking studies predicted a shift of EVG or COBI binding to the active site of CYP3A4 in the presence of ethanol.	Cobicistat	44-48	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	79-85
26566368-3	2015	The rationale behind COBI development was to provide an alternative to ritonavir (RTV) as a protease inhibitor pharmacoenhancer, due to associated adverse events with short- and long-term RTV use, such as gastrointestinal intolerability, drug-drug interactions, insulin resistance, lipodystrophy, and hyperlipidemia.	Cobicistat	21-25	insulin	Homo sapiens	262-269
26347243-1	2015	INTRODUCTION: We present what we believe to be the first case in the literature of rhabdomyolysis-induced renal failure caused by a probable drug interaction between elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate (EVG/COBI/FTC/TDF) and pravastatin/fenofibrate.	Cobicistat	179-189	sex determining region Y	Homo sapiens	248-251
26319088-11	2015	Moreover, as cobicistat is metabolized predominantly by CYP3A, plasma concentrations may increase or decrease on coadministration with CYP3A inhibitors or inducers, respectively.	Cobicistat	13-23	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	56-61
26319088-11	2015	Moreover, as cobicistat is metabolized predominantly by CYP3A, plasma concentrations may increase or decrease on coadministration with CYP3A inhibitors or inducers, respectively.	Cobicistat	13-23	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	135-140
26035169-0	2015	Rezolsta  (Darunavir/Cobicistat): First Boosted Protease Inhibitor Co-formulated with Cobicistat.	Cobicistat	21-31	serpin family A member 13, pseudogene	Homo sapiens	48-66
26035169-1	2015	Rezolsta  (darunavir/cobicistat) is the first boosted protease inhibitor in a fixed-dose combination to be approved for the treatment of HIV infection.	Cobicistat	21-31	serpin family A member 13, pseudogene	Homo sapiens	54-72
24375014-8	2014	Elvitegravir and cobicistat inhibited BCRP and OATP in vitro, emtricitabine and TDF did not.	Cobicistat	17-27	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	38-42
24646860-7	2014	Similar to cimetidine and ritonavir, cobicistat had the greatest effect on MATE1 with a 50% inhibition constant of 0.99 muM for creatinine transport.	Cobicistat	37-47	solute carrier family 47 member 1	Homo sapiens	75-80
24798279-3	2014	Since ritonavir-boosted regimens are associated with long-term adverse events, cobicistat, a CYP3A4 inhibitor without antiviral activity, has been developed.	Cobicistat	79-89	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	93-99
25350960-1	2014	OBJECTIVE: To describe baseline and emergent HIV-1 resistance to elvitegravir/ cobicistat/emtricitabine/tenofovir DF (EVG/COBI/FTC/TDF) and ritonavir-boosted atazanavir/emtricitabine/tenofovir DF (ATV+RTV+FTC/TDF) in HIV-1-infected, treatment-naive subjects through 144 weeks.	Cobicistat	79-89	sex determining region Y	Homo sapiens	131-134
24375014-8	2014	Elvitegravir and cobicistat inhibited BCRP and OATP in vitro, emtricitabine and TDF did not.	Cobicistat	17-27	solute carrier organic anion transporter family member 1A2	Homo sapiens	47-51
24900196-1	2010	Cobicistat (3, GS-9350) is a newly discovered, potent, and selective inhibitor of human cytochrome P450 3A (CYP3A) enzymes.	Cobicistat	0-10	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	88-106
24412072-6	2014	Through these efforts, a potent and selective inhibitor of CYP3A, GS-9350 (cobicistat) with improved physiochemical properties was discovered.	Cobicistat	75-85	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	59-64
24805065-3	2014	Currently, the CYP3A4 inhibitor ritonavir and its derivative cobicistat are prescribed to HIV patients as pharmacoenhancers.	Cobicistat	61-71	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	15-21
25030944-1	2014	Elvitegravir/cobicistat/emtricitabine/tenofovirDF (EVG/COBI/FTC/TDF) is the new single-tablet, fixed-dose formulation containing an integrase strand transfer inhibitor recently approved as antiretroviral treatment.	Cobicistat	13-23	sex determining region Y	Homo sapiens	64-67
23746300-1	2013	Cytochrome P450 3A4 (CYP3A4) inhibitors ritonavir and cobicistat, currently administered to HIV patients as pharmacoenhancers, were designed on the basis of the chemical structure/activity relationships rather than the CYP3A4 crystal structure.	Cobicistat	54-64	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	0-19
23746300-1	2013	Cytochrome P450 3A4 (CYP3A4) inhibitors ritonavir and cobicistat, currently administered to HIV patients as pharmacoenhancers, were designed on the basis of the chemical structure/activity relationships rather than the CYP3A4 crystal structure.	Cobicistat	54-64	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	21-27
23746300-1	2013	Cytochrome P450 3A4 (CYP3A4) inhibitors ritonavir and cobicistat, currently administered to HIV patients as pharmacoenhancers, were designed on the basis of the chemical structure/activity relationships rather than the CYP3A4 crystal structure.	Cobicistat	54-64	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	219-225
23616950-1	2013	Cobicistat is a novel cytochrome P450 3A4 (CYP3A4) inhibitor in advanced clinical evaluation for use as a pharmacoenhancer of antiretroviral drugs.	Cobicistat	0-10	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	22-41
23616950-1	2013	Cobicistat is a novel cytochrome P450 3A4 (CYP3A4) inhibitor in advanced clinical evaluation for use as a pharmacoenhancer of antiretroviral drugs.	Cobicistat	0-10	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	43-49
22850510-1	2012	The experimental pharmacoenhancer cobicistat (COBI), a potent mechanism-based inhibitor of cytochrome P450 3A enzymes, was found to inhibit the intestinal efflux transporters P-glycoprotein and breast cancer resistance protein.	Cobicistat	34-44	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	194-226
22850510-1	2012	The experimental pharmacoenhancer cobicistat (COBI), a potent mechanism-based inhibitor of cytochrome P450 3A enzymes, was found to inhibit the intestinal efflux transporters P-glycoprotein and breast cancer resistance protein.	Cobicistat	46-50	ATP binding cassette subfamily G member 2 (Junior blood group)	Homo sapiens	194-226
24900196-0	2010	Cobicistat (GS-9350): A Potent and Selective Inhibitor of Human CYP3A as a Novel Pharmacoenhancer.	Cobicistat	0-10	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	64-69
24343782-2	2014	Cobicistat has a lower potential for off-target drug interactions than the standard boosting agent ritonavir, due to its more selective inhibition of CYP3A and lower likelihood for enzymatic induction, and is devoid of anti-HIV activity.	Cobicistat	0-10	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	150-155
24100879-9	2013	The selective cytochrome P450 3A4 inhibitor cobicistat is a better tolerated alternative to ritonavir for pharmacokinetic "boosting", but may also result in clinically undesirable drug interactions.	Cobicistat	44-54	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	14-33
23896476-2	2013	COBI and TFV have been reported to interact with distinct transporters in renal proximal tubules; while TFV is renally eliminated by a combination of glomerular filtration and tubular secretion via anion transporters OAT1, OAT3, and MRP4, COBI inhibits renal cation transporters, particularly MATE1, resulting in a measurable decrease in the tubular secretion of creatinine.	Cobicistat	0-4	solute carrier family 22 member 6	Homo sapiens	217-221
23896476-2	2013	COBI and TFV have been reported to interact with distinct transporters in renal proximal tubules; while TFV is renally eliminated by a combination of glomerular filtration and tubular secretion via anion transporters OAT1, OAT3, and MRP4, COBI inhibits renal cation transporters, particularly MATE1, resulting in a measurable decrease in the tubular secretion of creatinine.	Cobicistat	0-4	solute carrier family 22 member 8	Homo sapiens	223-227
23896476-2	2013	COBI and TFV have been reported to interact with distinct transporters in renal proximal tubules; while TFV is renally eliminated by a combination of glomerular filtration and tubular secretion via anion transporters OAT1, OAT3, and MRP4, COBI inhibits renal cation transporters, particularly MATE1, resulting in a measurable decrease in the tubular secretion of creatinine.	Cobicistat	0-4	ATP binding cassette subfamily C member 4	Homo sapiens	233-237
23896476-2	2013	COBI and TFV have been reported to interact with distinct transporters in renal proximal tubules; while TFV is renally eliminated by a combination of glomerular filtration and tubular secretion via anion transporters OAT1, OAT3, and MRP4, COBI inhibits renal cation transporters, particularly MATE1, resulting in a measurable decrease in the tubular secretion of creatinine.	Cobicistat	0-4	solute carrier family 47 member 1	Homo sapiens	293-298
23703578-11	2013	Cobicistat is a new potent CYP3A inhibitor that is combined with elvitegravir and will be combined with HIV-PIs in the future.	Cobicistat	0-10	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	27-32
22321026-7	2012	Trials investigating the efficacy of once-daily co-formulated elvitegravir/cobicistat/emtricitabine/tenofovir (EVG/COBI/FTC/TDF) demonstrate a high rate of virologic suppression with fewer CNS and psychiatric adverse events compared with co-formulated efavirenz/emtricitabine/tenofovir.	Cobicistat	75-85	sex determining region Y	Homo sapiens	124-127
21348537-6	2011	The presence of a strong CYP3A inhibitor such as ritonavir or cobicistat renders the potential for increase in systemic exposures of CYP3A substrates coadministered with boosted elvitegravir.	Cobicistat	62-72	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	25-30
21348537-6	2011	The presence of a strong CYP3A inhibitor such as ritonavir or cobicistat renders the potential for increase in systemic exposures of CYP3A substrates coadministered with boosted elvitegravir.	Cobicistat	62-72	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	133-138
24900196-1	2010	Cobicistat (3, GS-9350) is a newly discovered, potent, and selective inhibitor of human cytochrome P450 3A (CYP3A) enzymes.	Cobicistat	0-10	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	108-113
35229634-3	2022	Here, we show that cobicistat, which is an FDA-approved drug booster that blocks the activity of the drug-metabolizing proteins cytochrome P450-3As (CYP3As) and P-glycoprotein (P-gp), inhibits SARS-CoV-2 replication.	Cobicistat	19-29	ATP binding cassette subfamily B member 1	Homo sapiens	161-175
34934565-4	2021	This report presents a patient who received a femoral artery stent and developed a large retroperitoneal hemorrhage after she was prescribed apixaban in addition to her antiretroviral therapy (AVT) regimen that included cobicistat, a strong CYP3A4 inhibitor.	Cobicistat	220-230	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	241-247
35598441-2	2022	We investigated the safety, tolerability, and pharmacokinetics of a multidose SJ733 regimen and a single-dose pharmacoboost approach using cobicistat to inhibit CYP3A4, thereby increasing exposure.	Cobicistat	139-149	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	161-167
34185564-11	2021	The incremental QALY and cost savings for DTG/3TC compared with DTG/abacavir(ABC)/3TC, cobicistat-boosted darunavir(DRV/c)/tenofovir alafenamide(TAF)/FTC, and bictegravir (BIC)/TAF/FTC, based on NMA results were 0.465, 0.142, and 0.698, and $42,948, $122,846, and $44,962, respectively.	Cobicistat	87-97	TATA-box binding protein associated factor 8	Homo sapiens	145-148
35229634-3	2022	Here, we show that cobicistat, which is an FDA-approved drug booster that blocks the activity of the drug-metabolizing proteins cytochrome P450-3As (CYP3As) and P-glycoprotein (P-gp), inhibits SARS-CoV-2 replication.	Cobicistat	19-29	ATP binding cassette subfamily B member 1	Homo sapiens	177-181
35229634-4	2022	Two independent cell-to-cell membrane fusion assays showed that the antiviral effect of cobicistat is exerted through inhibition of spike protein-mediated membrane fusion.	Cobicistat	88-98	surface glycoprotein	Severe acute respiratory syndrome coronavirus 2	132-137
35229634-7	2022	This was consistent with the effects of cobicistat on two of its known targets, CYP3A4 and P-gp, the silencing of which boosted the in vitro antiviral activity of remdesivir in a cobicistat-like manner.	Cobicistat	40-50	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	80-86
35229634-7	2022	This was consistent with the effects of cobicistat on two of its known targets, CYP3A4 and P-gp, the silencing of which boosted the in vitro antiviral activity of remdesivir in a cobicistat-like manner.	Cobicistat	40-50	phosphoglycolate phosphatase	Homo sapiens	91-95
35229634-7	2022	This was consistent with the effects of cobicistat on two of its known targets, CYP3A4 and P-gp, the silencing of which boosted the in vitro antiviral activity of remdesivir in a cobicistat-like manner.	Cobicistat	179-189	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	80-86
35229634-7	2022	This was consistent with the effects of cobicistat on two of its known targets, CYP3A4 and P-gp, the silencing of which boosted the in vitro antiviral activity of remdesivir in a cobicistat-like manner.	Cobicistat	179-189	phosphoglycolate phosphatase	Homo sapiens	91-95
33300183-1	2021	In AMBER and EMERALD, darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) 800/150/200/10mg demonstrated high virological response and low virological failure (VF) through week 96.	Cobicistat	32-42	TATA-box binding protein associated factor 8	Homo sapiens	86-89
33830489-3	2021	We report three cases of cobicistat-tacrolimus co-administration, two of which also include the co-administration of mTOR inhibitors, in HIV-positive patients undergoing SOT (2 kidney and 1 liver recipient).	Cobicistat	25-35	mechanistic target of rapamycin kinase	Homo sapiens	117-121
33501995-1	2021	BACKGROUND: Cobicistat, dolutegravir and rilpivirine are all modest inhibitors of proximal tubular creatinine secretion (IPTCrS) and hence a moderate and early non-progressive creatinine estimated glomerular filtration rate (Cr-eGFR) reduction has been observed in clinical trials.	Cobicistat	12-22	epidermal growth factor receptor	Homo sapiens	228-232
33629115-0	2021	Targeting xenobiotic nuclear receptors PXR and CAR to prevent cobicistat hepatotoxicity.	Cobicistat	62-72	nuclear receptor subfamily 1 group I member 2	Homo sapiens	39-42
33629115-0	2021	Targeting xenobiotic nuclear receptors PXR and CAR to prevent cobicistat hepatotoxicity.	Cobicistat	62-72	nuclear receptor subfamily 1 group I member 3	Homo sapiens	47-50
33398250-8	2020	We found that cobicistat is the most efficient inhibitor of Mpro both in silico and in vitro.	Cobicistat	14-24	NEWENTRY	Severe acute respiratory syndrome-related coronavirus	60-64
33222380-0	2021	Pharmacoenhancement of Low Crizotinib Plasma Concentrations in Patients with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer using the CYP3A Inhibitor Cobicistat.	Cobicistat	166-176	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	150-155
33222380-3	2021	We investigated whether the CYP3A inhibitor cobicistat increases Cmin,ss of the CYP3A substrate crizotinib in patients with low exposure.	Cobicistat	44-54	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	28-33
33222380-3	2021	We investigated whether the CYP3A inhibitor cobicistat increases Cmin,ss of the CYP3A substrate crizotinib in patients with low exposure.	Cobicistat	44-54	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	80-85
32140912-11	2020	CYP3A4 inhibitors such as ritonavir or cobicistat may increase the chance of this adverse effect.	Cobicistat	39-49	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	0-6
31516033-1	2020	Darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) 800/150/200/10 mg is being investigated in two Phase III trials.	Cobicistat	10-20	TATA-box binding protein associated factor 8	Homo sapiens	64-67
32741313-6	2021	Our studies have identified six potential inhibitors of Mpro enzyme, out of which four are commercially available FDA approved drugs (Cobicistat, Iopromide, Cangrelor, and Fortovase) and two are from Specs database of natural compounds (Hopeaphenol and Cyclosieversiodide-A).	Cobicistat	134-144	NEWENTRY	Severe acute respiratory syndrome-related coronavirus	56-60
32479865-2	2020	METHODS: Prezcobix/Rezolsta is a fixed-dose combination of 800 mg of the HIV protease inhibitor darunavir (DRV) and 150 mg cobicistat, a CYP3A4 inhibitor, which is indicated in combination with other antiretroviral agents for the treatment of HIV infection.	Cobicistat	123-133	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	137-143
32684114-4	2021	The results showed that DB02388 and Cobicistat (DB09065) exhibited potential binding affinities towards Mpro over 100 ns MD simulations, with binding energy values of -49.67 and -46.60 kcal/mol, respectively.	Cobicistat	36-46	NEWENTRY	Severe acute respiratory syndrome-related coronavirus	104-108
32684114-6	2021	The potency of DB02388 and Cobicistat is attributed to their abilities to form several hydrogen bonds with the essential amino acids inside the active site of Mpro.	Cobicistat	27-37	NEWENTRY	Severe acute respiratory syndrome-related coronavirus	159-163
32984524-2	2020	The prompt recognition of this drug-drug interaction is critical to avoid adverse outcomes when glucocorticoids are used with anti-retroviral treatment containing cobicistat, a potent cytochrome P450 3A (CYP3A4) inhibitor.	Cobicistat	163-173	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	204-210
32984524-12	2020	Conclusion: It is essential to avoid drugs that include cobicistat when administering glucocorticoids that are metabolized via the CYP3A4 pathway due to the risk of developing Cushing syndrome and secondary adrenal insufficiency.	Cobicistat	56-66	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	131-137